There are only three trees of the species Abies beshanzuensis left, but one of its molecules may pave the way for new cancer treatments.
Read more
Category: biotech/medical – Page 2243
Ophthalmology company Kejako (Geneva, Switzerland) has developed what it calls a noninvasive “Phakorestoration” process, whereby a laser patterns the lens of the eye of a presbyopia patient to restore clear vision just at the level needed for the patient to avoid wearing eyeglasses. This Phakorestoration process is repeated at intervals spanning several years over a patient’s lifetime, prolonging glasses-free vision for as long as 20 years.
By modeling the complete optical parameters of the human eye using COMSOL Multiphysics software, a prescription for a series of noninvasive laser procedures for presbyopia patients can provide glasses-free vision for more than 20 years.
Read more
Many people are at the very least iffy about the idea of extending human healthy lifespan through medical biotechnologies that prevent age-related diseases essentially by rejuvenating the body. Even people who accept the possibility that such therapies can be developed are not convinced that developing them is a good idea, and there are only a few arguments that most people use. These arguments can actually be easily adapted to make a case against the medicine that already exists, which the vast majority of people on the planet currently benefit from—and the consensus is virtually universal that people who do not yet benefit from it should be given this opportunity as soon as possible.
The question is: would people who accept these arguments as valid objections to rejuvenation accept them also as valid objections against “normal” medicine? For example, how many present-day people would agree with what these two people from the 1600s are talking about?
A – Did you hear about John’s son?
Read more
Both genes and the environment shape a person’s risk of disease, but while genes are frequently cataloged, perturbed, activated, turned off and systematically tested in the lab, environmental exposures are often studied as one-offs. Now Harvard Medical School investigators at Brigham and Women’s Hospital have developed an approach to systematically and simultaneously evaluate the effects of hundreds of environmental factors on the development of neurological diseases.
Through a series of investigations, the team has identified environmental factors that boost neurological inflammation, including an herbicide used in the United States but currently banned in Europe. Details of the team’s approach and findings are published Jan. 17 in Cell.
Read more
In the future, industrial robots may create jobs, boost productivity and spur higher wages. But one thing seems more certain for now: They’re vulnerable to hackers.
Factories, hospitals and other big robot users often lack sufficient levels of defense against a digital attack, according to cybersecurity experts, robot manufacturers and engineering researchers. The risk levels are rising as more robots morph from being offline and isolated to being internet-connected machines, often working alongside humans.
5G promises to make factories a lot smarter. And that means they’ll be a lot more vulnerable.
Read more
Engineers at the University of Maryland (UMD) have created the first 3D-printed fluid circuit element so tiny that 10 could rest on the width of a human hair. The diode ensures fluids move in only a single direction—a critical feature for products like implantable devices that release therapies directly into the body.
Read more
A new drug shows potential to halt cancer cells’ growth by stunting the cells’ biological clock.
The findings from scientists at the USC Michelson Center for Convergent Bioscience and Nagoya University’s Institute of Transformative BioMolecules (ITbM) advance a burgeoning area of research: turning the body’s circadian rhythms against cancer.
Their study, conducted on human kidney cancer cells and on acute myeloid leukemia in mice, was published Jan. 23 in the journal Science Advances.
Read more
By Debora MacKenzie
If you bled when you brushed your teeth this morning, you might want to get that seen to. We may finally have found the long-elusive cause of Alzheimer’s disease: Porphyromonas gingivalis, the key bacteria in chronic gum disease.
That’s bad, as gum disease affects around a third of all people. But the good news is that a drug that blocks the main toxins of P. gingivalis is entering major clinical trials this year, and research published today shows it might stop and even reverse Alzheimer’s. There could even be a vaccine.
Read more